Γαληνός - Βιβλιογραφία - TAMIFLU Powder for oral suspension
Γαληνός - Βιβλιογραφία - TAMIFLU Powder for oral suspension
Γαληνός - Βιβλιογραφία - TAMIFLU Powder for oral suspension
Each ml of reconstituted suspension contains oseltamivir phosphate equivalent to 6 mg of oseltamivir. One bottle of
reconstituted suspension (65 ml) contains 390 mg of oseltamivir. Excipients with known ...
Pharmaceutical form
Powder for oral suspension. The powder is a granulate or clumped granulate with a white to light yellow colour.
Therapeutic indications
Treatment of influenza Tamiflu is indicated in adults and children including full term neonates who present with
symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy ...
Posology Tamiflu suspension and Tamiflu hard capsules are bioequivalent formulations. 75 mg doses can be
administered as either one 75 mg capsule or one 30 mg capsule plus one 45 mg capsule or by administering ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Oseltamivir is effective only against illness caused by influenza viruses. There is no evidence for efficacy of
oseltamivir in any illness caused by agents other than influenza viruses (see section 5.1). ...
Pharmacokinetic properties of oseltamivir, such as low protein binding and metabolism independent of the CYP450
and glucuronidase systems (see section 5.2), suggest that clinically significant drug interactions ...
Pregnancy Influenza is associated with adverse pregnancy and foetal outcomes, with a risk of major congenital
malformations, including congenital heart defects. A large amount of data on oseltamivir exposure ...
Undesirable effects
Summary of the safety profile The overall safety profile of Tamiflu is based on data from 6049 adult/adolescent and
1473 paediatric patients treated with Tamiflu or placebo for influenza, and on data from ...
Overdose